Name : Mouse GPA33/A33 Protein
Product Source :
Recombinant Mouse GPA33/A33 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Leu22-Ile235.[Accession | NP_067623.1]
Molecular Weight :
The protein has a predicted MW of 24.91 kDa. Due to glycosylation, the protein migrates to 38-48 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Mouse GPA33 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Mouse GPA33 is greater than 95% as determined by SEC-HPLC.
Background :
Glycoprotein A33 (GPA33) is also known as Cell surface A33 antigen, is a single-pass type I membrane protein which is expressed in normal gastrointestinal epithelium and in 95% of colon cancers. GPA33 The predicted mature protein has a 213-amino acid extracellular region, a single transmembrane domain, and a 62-amino acid intracellular tail. The sequence of the extracellular region contains 1 Ig-like C2-type (immunoglobulin-like) domain and 1 Ig-like V-type (immunoglobulin-like) domain characteristic of the CD2 subgroup of the immunoglobulin (Ig) superfamily, which contains. GPA33 may play a role in cell-cell recognition and signaling.
Synonyms :
GPA33; A33; Cell surface A33 antigen; Glycoprotein A33; mA33
References & Citations :
(1)Hurwitz H , Crocenzi T , Lohr J , et al. A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma[J]. Journal for Immunotherapy of Cancer, 2014, 2(Suppl 3):P86-P86.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
ANGPTL8/Angiopoietin-like 8 Protein
CAMK1 Protein
Popular categories:
Toll-like Receptor 3
Complement Component 6